These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23873170)

  • 1. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
    Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
    Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
    Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
    Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
    Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
    Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.
    Arnold CN; Goel A; Compton C; Marcus V; Niedzwiecki D; Dowell JM; Wasserman L; Inoue T; Mayer RJ; Bertagnolli MM; Boland CR
    Cancer Biol Ther; 2004 Jan; 3(1):73-8. PubMed ID: 14726676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans.
    Ashktorab H; Smoot DT; Farzanmehr H; Fidelia-Lambert M; Momen B; Hylind L; Iacosozio-Dononue C; Carethers JM; Goel A; Boland CR; Giardiello FM
    Int J Cancer; 2005 Oct; 116(6):914-9. PubMed ID: 15856472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
    Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
    Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
    Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
    Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
    Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
    Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
    World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
    Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
    Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
    Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
    Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
    Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
    Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
    Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
    Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.